Analystreport

Eiger Biopharmaceuticals Inc. (NASDAQ: EIGR) is now covered by analysts at B. Riley. They set a "buy" rating and a $24.00 price target on the stock.

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com